Amphastar Pharmaceuticals (AMPH) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $0.78.
- Amphastar Pharmaceuticals' Debt to Equity fell 430.64% to $0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.78, marking a year-over-year decrease of 430.64%. This contributed to the annual value of $0.82 for FY2024, which is 1092.94% down from last year.
- Per Amphastar Pharmaceuticals' latest filing, its Debt to Equity stood at $0.78 for Q3 2025, which was down 430.64% from $0.8 recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Debt to Equity registered a high of $1.07 during Q3 2023, and its lowest value of $0.08 during Q2 2021.
- Moreover, its 5-year median value for Debt to Equity was $0.78 (2025), whereas its average is $0.52.
- In the last 5 years, Amphastar Pharmaceuticals' Debt to Equity soared by 61618.51% in 2023 and then crashed by 2358.49% in 2024.
- Over the past 5 years, Amphastar Pharmaceuticals' Debt to Equity (Quarter) stood at $0.17 in 2021, then decreased by 16.92% to $0.14 in 2022, then surged by 542.83% to $0.92 in 2023, then decreased by 10.93% to $0.82 in 2024, then fell by 4.53% to $0.78 in 2025.
- Its Debt to Equity stands at $0.78 for Q3 2025, versus $0.8 for Q2 2025 and $0.8 for Q1 2025.